No images? Click here
PMG Research Announces Capacity for Coronavirus Vaccine Trials
In an effort to support our industry's evolving coronavirus vaccine development needs, all PMG sites have capacity and resources available to rapidly initiate coronavirus vaccine trials.
Vaccine Experience
- C. Difficile
- Cytomegalovirus (CMV)
- E. Coli
- Herpes Zoster
- Human Papilloma Virus
- Influenza (seasonal)
- Measles/Mumps/Rubella (MMR)
- Meningococcal
- Pneumococcal
- Respiratory Syncytial Virus (RSV)
- Rotavirus
- Shingles
- Staph Aureus
- Tdap
- Tetanus
Pandemic & Public Health Vaccine Development Experience
- Dengue Fever
- Ebola
- Pandemic Influenza (H1N1/swine, H5N1/avian)
- Smallpox
- Tuberculosis
Excellence in Delivery
- Over 350 vaccine trials randomizing 21,500+ volunteers
- Fully enrolled or exceeded goal for 99% of vaccine trials
- Rapid start-up & multi-site SIVs and activation
- Data entry and query resolution within 24 hours
- Access to pediatric through geriatric populations
- High-volume, rapid-timeline enrollment process
Case Studies
- Enrolled 1505 volunteers in an influenza vaccine trial across 9 sites, 445 of whom were enrolled in one Sunday.
- Enrolled 1251 volunteers across 5 sites for a Respiratory Syncytial Virus (RSV) vaccine trial, with a screen fail rate of 1.8%, in 4 weeks.
